TG Therapeutics (TGTX)
(Delayed Data from NSDQ)
$16.55 USD
-0.21 (-1.25%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $16.55 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Brokerage Reports
TG Therapeutics, Inc. [TGTX]
Reports for Purchase
Showing records 261 - 277 ( 277 total )
Company: TG Therapeutics, Inc.
Industry: Medical - Products
3Q13 Results; Laser Focus for Their "Hot Targets"; Valuation Compelling
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Compelling Valuation and Positioning Remains Strong; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
2Q13 Results; Gearing Up for Even More Data Flow This Year; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Principal Investigator Feedback on ASCO Ublituximab Study: Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Ublituximab Continues its Attack on Rituxan; ASCO Summary; Target to $15
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Nice Signals for Ublituximab from ASCO Abstract
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
1Q13 Results; Important Visibility Expected at ASCO, EHA, and Lugano
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Next Generation Ready to Fight Leukemia and Lymphoma; Initiating at Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J